Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7380   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,352 result(s) found. Displaying page 2,065 of 2,218.
    «« First « Previous 2061  2062  2063  2064  2065  2066  2067  2068  2069  Next» Last»»
    EudraCT Number: 2019-000159-14 Sponsor Protocol Number: CLL1818 Start Date*: 2019-09-17
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Prospective study on the incidence of hepatitis B virus reactivation in untreated patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive treated with Rituximab, Chemot...
    Medical condition: Chronic lymphocytic leukemia is a neoplasm of the lymphatic system characterized by an accumulation of B lymphocytes in peripheral blood, bone marrow and lymphatic organs. Diffuse Large Cell B Lymp...
    Disease: Version SOC Term Classification Code Term Level
    22.1 10021881 - Infections and infestations 10058827 Hepatitis B reactivation PT
    20.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004696-12 Sponsor Protocol Number: FACIALPARALYSIS Start Date*: 2020-01-15
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis
    Medical condition: hemifacial paralysis (3 to 6 of the House-Brackmann scale)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10016060 Facial palsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000987-14 Sponsor Protocol Number: TRAMANT-01 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO
    Full Title: Phase II Study: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovar...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002766-31 Sponsor Protocol Number: 1200.277 Start Date*: 2018-11-23
    Sponsor Name:UCL
    Full Title: A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma
    Medical condition: Chordoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008747 Chordoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001102-34 Sponsor Protocol Number: CML1315 Start Date*: 2015-09-15
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resi...
    Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002485-40 Sponsor Protocol Number: REBOOT-CNIC Start Date*: 2018-03-22
    Sponsor Name:CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC)
    Full Title: treatment with beta-blockers after myocardial infarction without reduced ejection fraction
    Medical condition: STEMI or NSTEMI patients being discharged from the index hospitalization with a LVEF>40% without previous heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000604-15 Sponsor Protocol Number: PTC-19-602325 Start Date*: 2020-10-29
    Sponsor Name:UNIVERSITÀ DEGLI STUDI "G. D'ANNUNZIO" CHIETI-PESCARA
    Full Title: Multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II study aimed at evaluating the efficacy and safety of “Zinco Solfato” in Mild Cognitive Impairment due to Alzheimer...
    Medical condition: Prodromic Alzheimer's disease with evidence of cerebral amyloidosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006756-22 Sponsor Protocol Number: VVS-2.1 Start Date*: 2009-07-09
    Sponsor Name:Neocutis
    Full Title: VVS study: the efficacy and safety of Bio-restorative Skin Cream in the local treatment of vulvar vestibulitis syndrome (VVS) compared with placebo.
    Medical condition: Vulvar vestibulitis syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000422-58 Sponsor Protocol Number: D4203C00011 Start Date*: 2013-07-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated T...
    Medical condition: Papillary Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071029 Thyroid cancer stage III PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071030 Thyroid cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072162 Thyroid cancer recurrent PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) IT (Completed) ES (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000495-14 Sponsor Protocol Number: D7913L00031 Start Date*: 2005-03-14
    Sponsor Name:ASTRAZENECA
    Full Title: A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCER
    Medical condition: OPERABLE PROSTATE CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10060862 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001294-84 Sponsor Protocol Number: OPBGC&RS2011-004_CA2012 Start Date*: 2012-09-03
    Sponsor Name:EDISON PHARMACEUTICALS INC.
    Full Title: Prospective open label trial to evaluate the maintenance of the efficacy and the long term safety of EPI-743 in children with Leigh Disease
    Medical condition: Leigh Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004111-37 Sponsor Protocol Number: BHC-ABT-001 Start Date*: 2014-10-22
    Sponsor Name:BUDAI HEPATOLÓGIAI CENTRUM
    Full Title: Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT 333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C Vírus Infection witb Cirrhosis
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003418-18 Sponsor Protocol Number: SMR2268/TheMIBSStudy Start Date*: 2012-01-09
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A Randomised, Double Blind, Placebo Controlled, Multi-centre, Parallel Group, Interventional Study of Mesalazine (Asacol®) Treatment in IBS and the Evaluation of Rectal Inflammatory Status using th...
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007545-13 Sponsor Protocol Number: Version 2.1 Start Date*: 2009-02-23
    Sponsor Name:Sahlgrenska Universitetssjukhuset
    Full Title: Nytt protokoll för ABO-inkompatibel levertransplantation med Mabthera® och immunadsorption: en pilotstudie.
    Medical condition: Patients with liverfailure above 18 years of age, who is submitted to the waiting list for a liver transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004499-47 Sponsor Protocol Number: ZENITH Start Date*: 2015-04-16
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A case control, phase II, monocentric, randomized study, utilizing Zinc as enhancer of immune recovery and immune reconstitution in auto-transplant for multiple myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001888-39 Sponsor Protocol Number: PGX-HT Start Date*: 2016-01-28
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: PHARMACOGENOMICS HYPERTENSION : A NEW APPROACH FOR PERSONALIZED MEDICINE ( PGX - HT )
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10051753 Vascular calcification PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002268-15 Sponsor Protocol Number: EMPA-1 Start Date*: 2016-09-29
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF EMPAGLIFLOZIN, A SGLT-2 INHIBITOR, ON ENDOGENOUS GLUCOSE PRODUCTION AND PLASMA GLUCAGON LE...
    Medical condition: Patients with end-stage renal disease (ESRD) with or without Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    21.1 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003126-16 Sponsor Protocol Number: CANA-1 Start Date*: 2016-10-27
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF THE ACUTE ADMINISTRATION OF THE SGLT-2 INHIBITOR CANAGLIFLOZIN ON CONTERREGULATORY RESPONS...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-005140-41 Sponsor Protocol Number: Saxa-Dapa1 Start Date*: 2017-05-10
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP, SINGLE CENTER PILOT STUDY OF THE ACUTE AND CHRONIC EFFECTS OF DAPAGLIFLOZIN PLUS SAXAGLIPTIN IN ADDITION TO METFORMIN VERSUS...
    Medical condition: Patients with type 2 diabetes poorly controlled with metformin
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    23.0 10027433 - Metabolism and nutrition disorders 10012607 Diabetes mellitus inadequate control PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016783-37 Sponsor Protocol Number: WS475202 Start Date*: 2010-01-07
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: The Effects of 18-Month Replacement with a Very Low Fixed Dose vs. Standard Dose of Growth Hormone (GH) on Insulin Sensitivity, Body Composition, Bone Mass, Lipids, Muscle Strength and Quality of L...
    Medical condition: Growth hormone deficiency in adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2061  2062  2063  2064  2065  2066  2067  2068  2069  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Aug 12 21:04:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA